Under a memorandum of understanding (MoU) signed with JDMas Commerce Sdn Bhd, Pharmaniaga’s OTC products will be registered, exported, distributed and marketed by JDMas in China through JD.com.

Subsequently, Pharmaniaga’s pharmaceutical products will also be made available to the Chinese market through the same channel.

JDMas will also provide regulatory advisory services as well as commercial trade and supply chain operations for the China market, Pharmaniaga said in a statement today.

Pharmaniaga group managing director Zulkarnain Md Eusope said the collaboration with JDMas was part of a strategy to enter the China market, especially in the consumer and wellness business.

“We aim to build a strong and sustainable strategic business partnership that benefits both parties,” Zulkarnain said.

“Expansion into the international market has always been one of our strategic business
goals, and we have already made our presence felt in South East Asia, the Gulf region and Europe market,” he added.

China, with a population of more than 1.4 billion, is a huge market by any standard, and with 570 million users, JD.com would be able to help Pharmaniaga tap in the market.

JDMas will be collaborating with Pharmaniaga to plan product placements on the JD.Com platform, through advertising campaigns, customer surveys, brand ambassadors and various other marketing strategies.

The collaboration between Pharmaniaga and JD.Com is expected to increase the current
revenue of Pharmaniaga’s top OTC products by 100% to 150% in the first year, with expected revenue projection to reach an estimated US$30 million (RM142 million) by 2025.